Guerra Pan Advisors LLC Grows Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Guerra Pan Advisors LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 897 shares of the medical equipment provider’s stock after acquiring an additional 87 shares during the period. Guerra Pan Advisors LLC’s holdings in Intuitive Surgical were worth $303,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ISRG. Portside Wealth Group LLC raised its holdings in shares of Intuitive Surgical by 8.2% in the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Intuitive Surgical by 58.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after buying an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth $230,000. Blair William & Co. IL raised its stake in Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after purchasing an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Intuitive Surgical by 21.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after buying an additional 129,194 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded up $5.09 during mid-day trading on Tuesday, reaching $382.45. 638,201 shares of the company traded hands, compared to its average volume of 1,622,066. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The company has a market capitalization of $135.56 billion, a price-to-earnings ratio of 75.03, a price-to-earnings-growth ratio of 5.97 and a beta of 1.36. The firm’s fifty day moving average is $388.13 and its two-hundred day moving average is $341.56.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, beating the consensus estimate of $1.48 by $0.12. The business had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.89 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.91 EPS. As a group, equities research analysts predict that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the sale, the director now directly owns 25,319 shares in the company, valued at $9,373,093.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares in the company, valued at $43,677.70. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.20, for a total transaction of $740,400.00. Following the sale, the director now owns 25,319 shares of the company’s stock, valued at $9,373,093.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 248,418 shares of company stock valued at $95,927,097. Corporate insiders own 0.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wells Fargo & Company upped their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research report on Friday, January 19th. Citigroup raised their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada lifted their price objective on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Mizuho boosted their price target on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Finally, Truist Financial boosted their price target on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $375.70.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.